Australia Says Its System Preserves Biologics Monopoly For Six Years

ATLANTA -- Australia is making the case to the United States and other Trans-Pacific Partnership (TPP) countries here that its domestic system effectively provides for at least six years of market exclusivity for biologic drugs, in an apparent effort to show flexibility to U.S. demands for an extended term for this advanced class of medicines, according to informed sources. This argument is notable because Australia made clear at the July TPP ministerial in Maui that it was not willing to...